Con: Treating Hepatitis C Virus With Direct-Acting Antivirals: Fear Not the Perceived Threat of Hepatocellular Carcinoma
|
|
- Giles Ford
- 5 years ago
- Views:
Transcription
1 CONTROVERSIES IN LIVER TRANSPLANTATION Con: Treating Hepatitis C Virus With Direct-Acting Antivirals: Fear Not the Perceived Threat of Hepatocellular Carcinoma Neil Mehta and Francis Y. Yao Division of Gastroenterology, Department of Medicine, University of California, San Francisco, San Francisco, CA What s the Alternative? Not Treating Hepatitis C Virus? Direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection achieve sustained virological response (SVR) rates exceeding 90% in clinical trials (1) and in the real-world setting. (2) Although some studies have suggested an increased risk of hepatocellular carcinoma (HCC) with DAA therapy, any discussion about potential dangers of DAAs must also address the risks inherent to the expected progression of liver disease by withholding HCV treatment. The most important benefit of achieving SVR is a reduction in liver-related and overall mortality compared with no treatment or lack of SVR. (3,4) A meta-analysis has suggested that SVR leads to a reduction in all-cause mortality by 50% overall and 74% among patients with cirrhosis. (3) Achieving SVR may result in the reversal of hepatic decompensation. (5) Not surprisingly, the advent of DAA therapy has coincided with a 32% reduction in liver transplantation (LT) wait-list registrations for HCV. (6) DAAs and the Threat of HCC: Where Is the Evidence? In this review, we examine published data involving DAA therapy and HCC risk in 3 scenarios: DAAs and de novo HCC, DAAs and recurrent HCC after resection or local-regional therapy (LRT), and DAA and HCC outcome before and after LT. Abbreviations: ANRS, Agence Nationale de Recherche sur le Sida; CUPILT, Compassionate Use of Protease Inhibitors in viral C Liver Transplantation; DAA, direct-acting antiviral; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; LRT, local-regional therapy; LT, liver transplantation; NA, not available; RFA, radiofrequency ablation; SVR, sustained virological response; TACE, transarterial chemoembolization. Address reprint requests to Neil Mehta, M.D., University of California, San Francisco, 513 Parnassus Avenue, Room S-357, San Francisco, CA Telephone: ; FAX: ; neil.mehta@ucsf.edu Copyright VC 2017 by the American Association for the Study of Liver Diseases. View this article online at wileyonlinelibrary.com. DOI /lt Potential conflict of interest: Nothing to report CONTROVERSIES IN LIVER TRANSPLANTATION DAAs AND DE NOVO HCC RISK The annual incidence of HCC in untreated HCV cirrhosis is 3%-7%. (7) A few studies have reported high de novo HCC incidence rates of 7%-9% within approximately 1 year after completion of DAAs in patients with HCV cirrhosis (Table 1). (8-10) These observations have fueled a debate about DAAs contributing to accelerated HCC development by 1 of several postulated mechanisms including diminished immune cancer surveillance with rapid viral clearance. (14) These studies, however, are limited by a small sample size and reliance on historic controls. The perceived higher rates of HCC development after achieving SVR with DAAs could be attributed to a higher baseline HCC risk in DAA-treated patients, who are generally older with
2 LIVER TRANSPLANTATION, Vol. 23, No. 12, 2017 TABLE 1. Summary of Studies Evaluating Risk of De Novo HCC After Initiation of DAA Therapy Receiving DAA, n Liver Disease Severity Incidence of De Novo HCC Studies suggesting increased risk of de novo HCC after DAAs (versus historic controls) Cardoso et al. (8) (2016) % cirrhosis 7.4% after median 12 months from viral suppression Kozbial et al. (9) (2016) 195 NA 6.6% within 13 months of DAA cessation Ravi et al. (10) (2017) % cirrhosis 9.1% within 6 months of DAA cessation Studies suggesting no increased risk of de novo HCC after DAA Kanwal et al. (11) (2017) 22,500 39% cirrhosis SVR: 0.90 per 100 patient-years No SVR: 3.5 per 100 patient-years Calleja et al. (2) (2017) % bridging fibrosis 52% cirrhosis 0.9% within 18 months of DAA Cheung et al. (12) (2016) % decompensated cirrhosis - 73% Child s B cirrhosis 10% Child s C cirrhosis Romano et al. (13) (2016) % bridging fibrosis (F3) 65% Child s A cirrhosis 7% Child s B cirrhosis 4% within 6 months of DAA (same incidence found in the other 261 not receiving DAA over a 6-month period); 2.5% in months 6-15 from DAA F3: 0.2 per 100 patient-years Child s A: 1.6 per 100 patient-years Child s B: 2.9 per 100 patients-years more advanced liver disease, when compared with interferon-treated historical controls. (15,16) A recent analysis by Kanwal et al. (11) of 22,500 DAA-treated HCV patients at 129 Veterans Health Administration sites has provided the strongest evidence to dispel the notion that SVR after DAA promotes de novo HCC development. Patients who achieved SVR had a significantly lower incidence of HCC compared with those without SVR (0.90 versus 3.5 per 100 patient-years, adjusted hazard ratio of 0.28), but the absolute risk for HCC remained high in those with cirrhosis despite SVR. Using a Spanish national database, Calleja et al. (2) found de novo HCC in only 0.9% (30/ 3233) within 18 months of DAA. In a study by Cheung et al. from the United Kingdom (12) of 671 patients with decompensated HCV cirrhosis, the 406 DAA-treated patients had a HCC incidence of 4% within 6 months of starting DAA therapy that was essentially identical to that in untreated patients, but the rates of hepatic decompensation were 18% and 28%, respectively. In a preliminary report involving 3075 HCV patients with advanced fibrosis receiving DAA therapy at 24 Italian centers, (13) the HCC incidence was 1.6 and 2.9 per 100 person-years in Child s A and B patients, respectively. Not only was this observed HCC incidence rate lower than that of untreated historical HCV patients, achieving SVR on adjusted analysis was associated with an 80% reduction in the risk of HCC. A cause for concern was that approximately half of those developing HCC within 6 months of starting DAA therapy had >3 nodules or an infiltrative appearance on imaging. (13) The study by Kanwal et al., (11) however, has alleviated concern about increased tumor aggressiveness following DAA therapy. The largest tumor size at HCC diagnosis was <5 cm in 92% and only 10% had stage T3 or T4 HCC. Judging from the results of these studies (Table 1), we believe that DAAs do not increase the risk of de novo HCC development after SVR. Patients with HCV cirrhosis who achieve SVR with DAAs remain at high risk for HCC (11) and should continue to undergo HCC surveillance. DAAs AND HCC RECURRENCE AFTER RESECTION OR LRT An even more contentious issue is whether DAA treatment increases the risk of HCC recurrence after resection or LRT. Following resection or ablation of HCC, the incidence of HCC recurrence is approximately 20% at 6 months. (17) Two recent studies have claimed higher than expected rates of early HCC recurrence after DAA treatment for HCV (Table 2). In a Spanish multicenter study, Reig et al. (18) reported HCC recurrence in 28% (16/58) who received DAA therapy at a median of 11 months after a complete response with resection, ablation, or transarterial chemoembolization (TACE), with a median time to HCC recurrence of 3.5 months after DAA. CONTROVERSIES IN LIVER TRANSPLANTATION 1597
3 LIVER TRANSPLANTATION, December 2017 TABLE 2. Summary of Studies Evaluating DAA and Risk of HCC Recurrence After Complete Response to Resection or LRT n Receiving DAAs, n (%) Follow-up HCC Recurrence Rate Studies suggesting increased risk of HCC recurrence after DAA Reig et al. (18) (2016) (100%) 6 months (median) from DAA Conti et al. (19) (2016) (100%) 12 months (median) from last HCC treatment to DAA Studies suggesting no increased risk of HCC recurrence after DAA ANRS (3 cohorts) (20) HEPATHER: (71%) DAA treated: 20 months (median) from DAA DAA untreated: 26 months (median) from complete response CirVir: (17%) 21 months (median) from complete response CUPILT*: (100%) 67 months (mean) from LT to DAA Cabibbo et al. (21) (2017) (100%) 2 months (mean) complete response to DAA ; median follow-up 9 months from DAA Calleja et al. (2) (2017) (100%) 20 months (mean) from complete response Minami et al. (22) (2016) (2.9%) DAA treated: 16 months from DAA 28%; median 3.5 months from DAA to HCC recurrence 29%; within 24 weeks of DAA completion DAA treated: 13% 0.73 per 100 person-months DAA untreated: 21% 0.66 per 100 person-months DAA treated: 1.1 per 100 person-months DAA untreated: 1.7 per 100 person-months 2.2%; 7 months (mean) from DAA to HCC recurrence 20% overall; 12% within 6 months of DAA 27% within 12 months of DAA 13% within 6 months of DAA 30% within 12 months of DAA 21% within 1 year of DAA (versus 31% in HCV-untreated patients) *Only LT recipients in this cohort. The subgroup receiving DAAs for less than 4 months after HCC treatment had the highest HCC recurrence risk at 41%. Conti et al. from Bologna, Italy (19) found a similar HCC recurrence rate of 29% (17/59) within 24 weeks of completing DAA therapy. These 2 studies share similar limitations including small sample size, short period of observation, and lack of a proper comparison group. Furthermore, other studies have questioned whether the threat of a higher HCC recurrence risk is real (Table 2). A multicenter French collaboration (Agence Nationale de Recherche sur le Sida [ANRS]) (20) analyzed 3 cohorts of HCV patients receiving curative HCC therapy (resection, ablation, or LT) and found no significant difference in HCC recurrence rates between DAA-treated and DAA-untreated controls. A multicenter Italian study (21) evaluated 143 patients who received DAAs at a median of 11 months after complete response to HCC therapy, and it found HCC recurrence rates of 12% and 27% at 6 and 12 months, respectively, not higher than that reported in the literature in DAAuntreated patients. Calleja et al. from Spain (2) reported a HCC recurrence rate of 13% within 6 months of starting DAAs in 70 patients who achieved complete response to HCC treatment. Minami et al. (22) from Japan evaluated HCV/HCC patients treated with radiofrequency ablation (RFA) and showed a HCC recurrence rate of 21% within 1 year in those who received DAAs after RFA (n 5 27), not significantly different when compared with a HCC recurrence rate of 31% in 861 controls not receiving HCV therapy after RFA. In a meta-analysis of 11 studies, (23) hepatic decompensation and not HCC recurrence has the greatest 1598 CONTROVERSIES IN LIVER TRANSPLANTATION
4 LIVER TRANSPLANTATION, Vol. 23, No. 12, 2017 impact on survival in cirrhotic HCV patients with early stage HCC and complete response after resection or ablation. Consequently, in the current state of rather weak evidence linking DAAs with accelerated HCC recurrence, patients with HCV cirrhosis who underwent resection or LRT for HCC should not be dissuaded from undergoing DAA therapy to prevent liver disease progression and decompensation. DAAs AND HCC OUTCOME BEFORE AND AFTER LT Two studies on HCV/HCC patients awaiting LT have reported no increased risk for dropout from the waiting list due to HCC progression following DAA treatment. Zanetto et al. from Padua, Italy (24) studied 46 wait-listed HCV/HCC patients and found no significant differences between DAA-treated (n 5 23) and untreated controls (n 5 23) in wait-list dropout due to HCC progression, explant pathology, or post- LT HCC recurrence. Huang et al. from our institution (25) evaluated 178 HCV/HCC patients receiving mostly TACE on the LT waiting list. The observed HCC recurrence (pre-lt) within 1 year after initial complete response to LRT was not significantly different when comparing 62 DAA-treated patients with 87 untreated controls (45% versus 49%, respectively). On adjusted analysis, those receiving DAAs after HCC diagnosis had a trend toward lower dropout risk compared with untreated patients (hazard ratio, 0.47; P ). It has been suggested that the SVR rate with DAA therapy is reduced if HCC is present. (26,27) In 1 study, the SVR was 97% if the HCC was treated versus only 58% in the presence of active HCC. (27) In this context, HCC should be controlled with LRT first before treating HCV with DAAs, and this may result in disease stabilization and even reduction in liver-related death on the waiting list. The decision regarding DAA treatment before versus after LT is complex, but it should take into account the degree of hepatic decompensation and availability of regional HCV-positive donor livers. (28) For LT recipients for HCC who received DAAs, data assessing the impact of DAAs on the risk of HCC recurrence after LT are scant. Yang et al. (29) reported a 27% (5/18) HCC recurrence rate after DAA therapy followed by LT versus 9.5% (6/63; P ) in those who did not receive DAAs prior to LT. In the Compassionate Use of Protease Inhibitors in viral C Liver Transplantation (CUPILT) cohort of the ANRS study, (21) 314 LT recipients who received DAAs after LT had HCC recurrence rate of only 2.2%. Nevertheless, DAAs were initiated at a mean of 67 months after LT, well beyond the period when most HCC recurrence would have occurred, and thus many with early post-lt HCC recurrence might have already been excluded from the study. More data on DAAs and the HCC recurrence risk after LT are needed. In the meantime, there is no reason to withhold DAA treatment in LT recipients, given the high efficacy of DAAs (20) and the substantial risk of accelerated liver disease progression and graft failure due to HCV reinfection. Results from large DAA treatment cohorts have dispelled the notion that SVR following DAAs promotes de novo HCC development. For HCV patients with established HCC who achieve complete response with resection or LRT, there is insufficient evidence to justify withholding DAA treatment and more robust data assessing HCC recurrence risk are needed. In HCV/HCC patients awaiting LT, there are additional factors when considering DAA therapy, but it does not appear to increase wait-list dropout or post-lt HCC recurrence. REFERENCES 1) Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med 2017;166: ) Calleja JL, Crespo J, Rincon D, Ruiz-Antoran B, Fernandez I, Perello C, et al.; for Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: results from a Spanish realworld cohort. J Hepatol 2017;66: ) Simmons B, Saleem J, Heath K, Cooke GS, Hill A. Long-term treatment outcomes of patients infected with hepatitis C virus: A systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis 2015; 61: ) van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308: ) Foster GR, Irving WL, Cheung MC, Walker AJ, Hudson BE, Verma S, et al.; for HCV Research, UK. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;64: ) Flemming JA, Kim WR, Brosgart CL, Terrault NA. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology 2017;65: ) European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL- CONTROVERSIES IN LIVER TRANSPLANTATION 1599
5 LIVER TRANSPLANTATION, December 2017 EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56, ) Cardoso H, Vale AM, Rodrigues S, Gonçalves R, Albuquerque A, Pereira P, et al. High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis. J Hepatol 2016;65: ) Kozbial K, Moser S, Schwarzer R, Laferl H, Al-Zoairy R, Stauber R, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. J Hepatol 2016;65: ) Ravi S, Axley P, Jones D, Kodali S, Simpson H, McGuire BM, Singal AK. Unusually high rates of hepatocellular carcinoma after treatment with direct-acting antiviral therapy for hepatitis C related cirrhosis. Gastroenterology 2017;152: ) Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El- Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 2017;153: ) Cheung MC, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;65: ) Romano A, Capra F, Piovesan S, Chemello L, Cavalletto L, Anastassopoulos G, et al. Incidence and pattern of de novo hepatocellular carcinoma in HCV patients treated with oral DAAs. Hepatology 2016;64(supp):10A. 14) Nault JC, Colombo M. Hepatocellular carcinoma and direct acting antiviral treatments: controversy after the revolution. J Hepatol 2016;65: ) El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection. Hepatology 2016;64: ) Toyoda H, Kumada T, Tada T. Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV. Hepatology 2016;64: ) Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, et al.; for STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015;16: ) Reig M, Mari~no Z, Perello C, I~narrairaegui M, Ribeiro A, Lens S, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016;65: ) Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65: ) ANRS collaborative study group on hepatocellular carcinoma. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol 2016;65: ) Cabibbo G, Petta S, Calvaruso V, Cacciola I, Cannavo MR, Madonia S, et al. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with directacting antivirals? a prospective multicentre study. Aliment Pharmacol Ther 2017;46: ) Minami T, Tateishi R, Nakagomi R, Fujiwara N, Sato M, Enooku K, et al. The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C- related hepatocellular carcinoma. J Hepatol 2016;65: ) Cabibbo G, Petta S, Barbara M, Attardo S, Bucci L, Farinati F, et al.; for Italian Liver Cancer (ITA.LI.CA) group. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. J Hepatol 2017;67: ) Zanetto A, Shalaby S, Vitale A, Mescoli C, Ferrarese A, Gambato M, et al. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals. Liver Transpl 2017;23: ) Huang AC, Mehta N, Dodge JL, Yao FY, Terrault NA. Directacting antivirals for hepatitis C do not increase the risk of hepatocellular carcinoma recurrence after locoregional therapy or liver transplant waitlist dropout. J Hepatol 2017;66(suppl):S97. 26) Beste LA, Green PK, Berry K, Kogut MJ, Allison SK, Ioannou GN. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. J Hepatol 2017;67: ) Prenner SB, VanWagner LB, Flamm SL, Salem R, Lewandowski RJ, Kulik L. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with directacting antivirals. J Hepatol 2017;66: ) Salazar J, Saxena V, Kahn JG, Roberts JP, Mehta N, Volk M, Lai JC. Cost-effectiveness of direct-acting antiviral treatment in hepatitis C-infected liver transplant candidates with compensated cirrhosis and hepatocellular carcinoma. Transplantation 2017;101: ) Yang JD, Aqel BA, Pungpapong S, Gores GJ, Roberts LR, Leise MD. Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. J Hepatol 2016;65: CONTROVERSIES IN LIVER TRANSPLANTATION
The Impact of DAA on HCC Occurrence
The Impact of DAA on HCC Occurrence Professeur Didier Samuel Centre Hépatobiliaire Inserm-Paris Sud Research Unit 1193 Departement Hospitalo Universitaire Hepatinov Hôpital Paul Brousse Université Paris
More informationHCC incidence and recurrence after DAAs: new insights
Örmeci. Hepatoma Res 2019;5:11 DOI: 10.20517/2394-5079.2019.14 Hepatoma Research Editorial Open Access HCC incidence and recurrence after DAAs: new insights Necati Örmeci Department of Gastroenterology,
More informationHepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan;
Editorial The unexpected high risk of occurrence or recurrence of hepatocellular carcinoma after successful antiviral therapy with interferon-free direct-acting antivirals Ming-Lung Yu 1,2,3, Chung-Feng
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
More informationAccepted Manuscript. Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: too alarming?
Accepted Manuscript Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: too alarming? Qing-Lei Zeng, Zhi-Qin Li, Hong-Xia Liang, Guang-Hua Xu, Chun-Xia
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
More informationHepatocellular Carcinoma Surveillance
Amit G. Singal, MD, MS Hepatocellular Carcinoma Surveillance Postgraduate Course: Challenges in Management of Common Liver Diseases 308 1 Patient Case 69 year-old otherwise healthy male with compensated
More informationAccepted Manuscript. S (16)30397-X Reference: JHEPAT To appear in: Journal of Hepatology
Accepted Manuscript High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis Helder Cardoso, Ana Maria Vale, Susana Rodrigues,
More informationDirect-acting antiviral treatment for hepatitis C in liver transplant candidates and recipients
Editorial Direct-acting antiviral treatment for hepatitis C in liver transplant candidates and recipients Nobuhisa Akamatsu, Junichi Togashi, Kiyoshi Hasegawa, Norihiro Kokudo Artificial Organ and Transplantation
More informationLife After SVR for Cirrhotic HCV
Life After SVR for Cirrhotic HCV KIM NEWNHAM MN, NP CIRRHOSIS CARE CLINIC UNIVERSITY OF ALBERTA Objectives To review the benefits of HCV clearance in cirrhotic patients To review some of the emerging data
More informationHepatocellular Carcinoma: Can We Slow the Rising Incidence?
Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline
More informationImpatto della clearance virale e rischio di carcinoma epatocellulare
EPATITE CRONICA DA HCV: Impatto della clearance virale e rischio di carcinoma epatocellulare Rodolfo Sacco, M.D., PhD Direttore U.O.C. Gastroenterologia ed Endoscopia Digestiva A.O.U. Ospedali Riuniti"
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More information3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice
3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice Rome, 13 December 2013 Management and monitoring of HCC in the future era of DAA s Prof. Massimo Colombo Chairman Department of Liver,
More informationLiver transplantation and hepatitis C virus
Liver transplantation and hepatitis C virus Where do we come from? Where are we? Where are we going? François Durand Hépatologie & Réanimation Hépato-Digestive INSERM U1149 Hôpital Beaujon, Clichy HCV:
More informationThe Short-Term Incidence of Hepatocellular Carcinoma Is Not Increased After Hepatitis C Treatment with Direct-Acting Antivirals: An ERCHIVES Study
The Short-Term Incidence of Hepatocellular Carcinoma Is Not Increased After Hepatitis C Treatment with Direct-Acting Antivirals: An ERCHIVES Study DK Li, YJ Ren, DS Fierer, S Rutledge, OS Shaikh, V Lo
More informationBest of EASL White Nights
Best of EASL White Nights Saint Petersburg 8 June 2017 Patients with HCC and HCV:do we really need to cure HCV? Massimo Colombo, MD Center for Translational Research in Hepatology,Humanitas Hospital, Rozzano,
More informationImpact of direct-acting antiviral agents on the development of hepatocellular carcinoma: evidence and pathophysiological issues
REVIEW ARTICLE Annals of Gastroenterology (2018) 31, 1-10 Impact of direct-acting antiviral agents on the development of hepatocellular carcinoma: evidence and pathophysiological issues Maria Tampaki a,
More information9th Paris Hepatitis Conference
9th Paris Hepatitis Conference Paris, 12 January 2016 Treatment of hepatocellular carcinoma: beyond international guidelines Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow Units
More informationIS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?
IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views
More informationHepatitis Alert: Management of Patients With HCV Who Have Achieved SVR
Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR This program is supported by educational grants from AbbVie, Gilead Sciences, and Merck About These Slides Please feel free to use,
More informationThe future of liver transplantation for viral hepatitis
The future of liver transplantation for viral hepatitis François Durand Hepatology & Liver Intensive Care Hospital Beaujon, Clichy University Paris Diderot France Liver transplantation in France 2013:
More informationXVII Annual Meeting of Hepatology
XVII Annual Meeting of Hepatology Malaga 18,19 May 2018 Chronic Hepatitis C and HCC : What is new? Massimo Colombo, MD Head,Humanitas Clinical and Research Center, Rozzano, Italy. Chairman,EASL International
More informationHCV care after cure. This program is supported by educational grants from
HCV care after cure This program is supported by educational grants from Raffaele Bruno,MD Department of Infectious Diseases, Hepatology Outpatients Unit University of Pavia Fondazione IRCCS Policlinico
More informationTREATMENT OF HEPATITIS C IN THE LIVER TRANSPLANT SETTING. Dra. Zoe Mariño Liver Unit. Hospital Clinic Barcelona
TREATMENT OF HEPATITIS C IN THE LIVER TRANSPLANT SETTING Dra. Zoe Mariño Liver Unit. Hospital Clinic Barcelona Hepatitis C after LT Survival (%) HCV negative HCV positive Time from LT (years) HCV treatment
More informationAntiviral treatment in HCV cirrhotic patients on waiting list
Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory
More informationHepatitis C - results in real life
Hepatitis C - results in real life Robert Flisiak Department of Infectious Diseases and Hepatology Medical University of Białystok, Poland 10th PHC Paris, 30-31 January 2017 Disclosures Advisor and/or
More informationScreening for HCCwho,
Screening for HCCwho, how and how often? Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital HCC Global Epidemiology
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationThe last four decades has seen a rising incidence
HEPATOLOGY COMMUNICATIONS, VOL. 1, NO. 1, 2017 Screening for Hepatocellular Carcinoma: What Is Missing? Neil J. Mehta, 1 Aygul Dogan Celik, 1,2 and Marion G. Peters 1 While there are guidelines from all
More informationManagement of HepatoCellular Carcinoma
9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma
More informationAASLD, Boston, USA, 10 th November 2014 [oral presentation]
Effects of Sustained Virological Response on the of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 34,563 patients with Hepatitis C infection. Andrew
More informationHepatitis C reinfection after sustained virological response in HIV/HCV co-infected patients
Hepatitis C reinfection after sustained virological response in HIV/HCV co-infected patients Fábio Videira Santos, Joana Fragoso, Ana Cipriano, Miguel Araújo Abreu, Olga Vasconcelos, Ana Aboim Horta, Ana
More informationThe impact of the treatment of HCV in developing Hepatocellular Carcinoma
The impact of the treatment of HCV in developing Hepatocellular Carcinoma Paul Y Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Gastroenterology/Hepatology Division Indiana University
More informationHepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany
Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany PHC 2018 - www.aphc.info Disclosures Advisory boards:
More informationChronic HCV infection affects up to 185 million
SPECIAL ARTICLE Hepatology Communications, VOL. 2, NO. 10, 2018 Liver Disease Monitoring Practices After Hepatitis C Cure in the Underserved Population Nicole J. Kim, 1,2 Catherine Magee, 2 Cassie Cummings,
More informationHepatocellular carcinoma
Hepatocellular carcinoma Mary Ann Y. Huang, M.D., M.S., FAASLD Transplant hepatologist Peak Gastroenterology Associates Porter Adventist Hospital Denver, Colorado Background - Worldwide Hepatocellular
More informationTitle: Hepatocellular carcinoma in patients without advanced fibrosis after eradication of HCV with antiviral treatment
Title: Hepatocellular carcinoma in patients without advanced fibrosis after eradication of HCV with antiviral treatment Authors: Yolanda Sánchez-Torrijos, Jara Eloísa Ternero Vega, Carmen Cepeda Franco
More informationExperience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona
Experience with pre-transplant antiviral treatment: PEG/RBV and DAA Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Interferon-free regimens G1b nulls Asunaprevir (PI) + Daclatasvir
More informationLiver transplantation: Hepatocellular carcinoma
Liver transplantation: Hepatocellular carcinoma Alejandro Forner BCLC Group. Liver Unit. Hospital Clínic. University of Barcelona 18 de marzo 2015 3r Curso Práctico de Transplante de Órganos Sólidos Barcelona
More informationThe Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:
The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present: Certified by: Provided by: Endorsed by: Hepatocellular Carcinoma HCC: Age
More informationHepatocellular carcinoma (HCC) is the
HEPATOLOGY, VOL. 67, NO. 6, 2018 AMERICAN ASSOCIATION FOR THE STUDY OFLIVERD I S E ASES The Short-Term Incidence of Hepatocellular Carcinoma Is Not Increased After Hepatitis C Treatment With Direct-Acting
More informationCurrent Status of HBV and Liver Transplant
Current Status of HBV and Liver HBV as Indication for Liver ation in U.S. Significant decrease in rate of wait listing for decompensated cirrhosis since 2003 (since s) No change in rate of wait listing
More informationAASLD Washington DC, USA Dr. Alexander Kim Chief Vascular and Interventional Radiology, Medstar Georgetown University Hospital
AASLD 2017 - Washington DC, USA Dr. Alexander Kim Chief Vascular and Interventional Radiology, Medstar Georgetown University Hospital THE CHANGING LANDSCAPE IN THE TREATMENT OF HCC DISCLAIMER Please note:
More informationReconsidering Liver Transplantation for HCC in a Era of Organ shortage
Reconsidering Liver Transplantation for HCC in a Era of Organ shortage Professor Didier Samuel Centre Hépatobiliaire Inserm-Paris Sud Research Unit 1193 Departement Hospitalo Universitaire Hepatinov Hôpital
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More information9/10/2018. Liver Transplant for Hepatocellular Carcinoma (HCC): What is New? DISCLOSURES
UCSF Transplant 2018: Pioneering Advances in Transplantation DISCLOSURES Liver Transplant for Hepatocellular Carcinoma (HCC): What is New? I have no relevant commercial interests or relationships to report
More informationLiver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?
Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure? María Reig, MD, PhD 1 Loreto Boix, MD, PhD 1 Zoe Mariño, MD, PhD 2 Ferran Torres, MD, PhD 2 Xavier Forns, MD,
More informationLiver transplant: what is left after the viruses
Riunione Monotematica A.I.S.F. 2016 The Future of Liver Disease: Beyond HCV is there a Role for Hepatologist? Milan 15 th 2016 Liver transplant: what is left after the viruses Stefano Ginanni Corradini
More informationHepatocellular Carcinoma: Diagnosis and Management
Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm
More informationHepatitis C Highlights from ILC / EASL 2016
Hepatitis C Highlights from ILC / EASL 2016 VIII International Update Workshop in Hepatology Curitiba, 26.08.2016 Christoph Sarrazin St. Josefs-Hospital Wiesbaden and Goethe-University, Frankfurt am Main
More informationIncreased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant
ORIGINAL ARTICLE July-August, Vol. 15 No. 4, 2016: 545-549 545 The Official Journal of the Mexican Association of Hepatology, the Latin-American Association for Study of the Liver and the Canadian Association
More informationAccepted Manuscript. Letter to the Editor. Reply to: From the CUPIC study: Great times are not coming (?)
Accepted Manuscript Letter to the Editor Reply to: From the CUPIC study: Great times are not coming (?) Christophe Hezode, Helene Fontaine, Yoann Barthe, Fabrice Carrat, Jean-Pierre Bronowicki PII: S0-()00-
More informationSEQUENCING OF HCC TREATMENT. Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA
SEQUENCING OF HCC TREATMENT Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA February 2018 DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationHepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC
Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Objectives Identify patient risk factors for hepatocellular carcinoma (HCC) Describe strategies
More informationAntiviral Therapy and Liver Cancer
Antiviral Therapy and Liver Cancer St. Petersburg, 070613 Markus Peck-Radosavljevic Gastroenterologie & Hepatologie AKH & Medizinische Universität Wien HCC Study Group Medizinische Universität Wien Prevention
More informationChronic viral hepatitis and liver disease in Belgium Pierre Deltenre
Chronic viral hepatitis and liver disease in Belgium Pierre Deltenre Brussels, November 7, 2017 Hepatitis B and C in Belgium What we need to know 1. Who is at risk of infection? 2. What is the natural
More information«Εκτίμηση κινδφνου ανάπτυξης ΗΚΚ σε ασθενείς με HCV λοίμωξη» Evaluation of HCC risk in HCV patients
«Εκτίμηση κινδφνου ανάπτυξης ΗΚΚ σε ασθενείς με HCV λοίμωξη» Evaluation of HCC risk in HCV patients Δημήτρησ Ν. αμωνάκησ Γαςτρεντερολογική κλινική Πανεπιςτημίου Κρήτησ Outline Epidemiology Risk factors
More informationHCC: Is it an oncological disease? - No
June 13-15, 2013 Berlin, Germany Prof. Oren Shibolet Head of the Liver Unit, Department of Gastroenterology Tel-Aviv Sourasky Medical Center and Tel-Aviv University HCC: Is it an oncological disease? -
More informationLiver Transplantation: The End of the Road in Chronic Hepatitis C Infection
University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2012 UMass Center for Clinical and Translational Science Research Retreat
More informationTreating HCV Prior to Liver Transplantation. What Are the Treatment Options? Xavier Forns Liver Unit Hospital Clinic, CIBEREHD, IDIBAPS Barcelona
Treating HCV Prior to Liver Transplantation What Are the Treatment Options? Xavier Forns Liver Unit Hospital Clinic, CIBEREHD, IDIBAPS Barcelona Disclosures Unrestricted Grant Support: Janssen and Abbvie
More informationSelection Criteria and Insertion of SIRT into HCC Treatment Guidelines
Selection Criteria and Insertion of SIRT into HCC Treatment Guidelines 2 nd Asia Pacific Symposium on Liver- Directed Y-90 Microspheres Therapy 1st November 2014, Singapore Pierce Chow FRCSE PhD SIRT in
More informationUnmet needs in intermediate HCC. Korea University Guro Hospital Ji Hoon Kim
Unmet needs in intermediate HCC Korea University Guro Hospital Ji Hoon Kim BCLC HCC Stage 0 PST 0, Child Pugh A Stage A C PST 0 2, Child Pugh A B Stage D PST > 2, Child Pugh C Very early stage (0) 1 HCC
More informationOptimizing Patient Selection, Organ Allocation, and Outcomes in Liver Transplant (LT) Candidates with Hepatocellular Carcinoma (HCC)
XXVI SETH Congress- 30 November 2017 Optimizing Patient Selection, Organ Allocation, and Outcomes in Liver Transplant (LT) Candidates with Hepatocellular Carcinoma (HCC) Neil Mehta, MD University of California,
More informationHIV coinfection and HCC
HIV coinfection and HCC 3 rd APASL STC on HCC 21 st -23 rd Nov 2013 Cebu, Phillippines George KK Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond) Consultant, Humanity and Health GI
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationAlpha-Fetoprotein-L3 for Detection of Hepatocellular (Liver) Cancer. Original Policy Date
MP 2.04.35 Alpha-Fetoprotein-L3 for Detection of Hepatocellular (Liver) Cancer Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature
More informationFollow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France
9th Paris Hepatitis Conference, January 11-12, 2016 Follow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France Disclosures
More informationSurveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice
Surveillance for Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationIL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE?
IL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE? Francesco Paolo Russo Department of Surgery, Oncology and Gastroenterology Multivisceral/ Gastroenterology Section University
More informationHCV Therapy in Liver Transplant Candidate
PHC 216 HCV Therapy in Liver Professor Didier SAMUEL Transplant Candidate Dr Audrey COILLY Centre Hépato-Biliaire, Inserm 1193 Treat before orrearch afuniter? University Paris Sud A Villejuif u d r e yfrance
More informationTumor incidence varies significantly, depending on geographical location.
Hepatocellular carcinoma is the 5 th most common malignancy worldwide with male-to-female ratio 5:1 in Asia 2:1 in the United States Tumor incidence varies significantly, depending on geographical location.
More informationUpdate on Hepatitis C. Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017
Update on Hepatitis C Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017 The global prevalence of HCV was 1 0% (95% uncertainty interval 0 8 1 1) in 2015: 71 1 million (62 5 79
More informationLong-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance
Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,
More informationChanging epidemiology of HCC in Italy
Changing epidemiology of HCC in Italy G. Svegliati-Baroni Clinica di Gastroenterologia SOS Epatopatie Croniche-Trapianto di Fegato Università Politecnica delle Marche, Ancona Worldwide estimated new PLC
More informationThe Effect of Antiviral Therapy on Liver Fibrosis in CHC. Jidong Jia Beijing Friendship Hospital, Capital Medical University
The Effect of Antiviral Therapy on Liver Fibrosis in CHC Jidong Jia Beijing Friendship Hospital, Capital Medical University 2016-5-29 1 Disclosure Consultation for Abbvie, BMS, Gilead, MSD, Novartis and
More informationLiver Pathology and the Clinician in 2015: At the Crossroads. Thomas D. Schiano, M.D. Mount Sinai Medical Center New York, New York
Liver Pathology and the Clinician in 2015: At the Crossroads Thomas D. Schiano, M.D. Mount Sinai Medical Center New York, New York DISCLOSURES Consultant for: Salix Merck Gilead BMS Synageva Research funding:
More informationDAAs in decompensated cirrhosis: pros and cons. C. Triantos University Hospital οf Patras
DAAs in decompensated cirrhosis: pros and cons C. Triantos University Hospital οf Patras Conflicts of interest Speaker and research/travel grants from MSD, Roche, Abbvie, Bristol-Myers Squibb, Bayer and
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More information3/22/2017. I will be discussing off label/investigational use of tivantinib for hepatocellular carcinoma.
Grant/Research Support - AbbVie, Conatus, Hologic, Intercept, Genfit, Gilead, Mallinckrodt, Merck, Salix, Shire, Vital Therapies Consultant AbbVie, Gilead, Merck Member, Scientific Advisory Board Vital
More informationHepatocellular Carcinoma (HCC): Burden of Disease
Hepatocellular Carcinoma (HCC): Burden of Disease Blaire E Burman, MD VM Hepatology Hepatocellular Carcinoma (HCC) Primary HCCs most often arise in the setting of chronic inflammation, liver damage, and
More informationHCV elimination : lessons from Scotland
HCV elimination : lessons from Scotland Sharon Hutchinson Glasgow Caledonian University / Health Protection Scotland BHIVA Hepatology Highlights, Edinburgh, 17 th April 2018 Disclosures Honoraria from
More informationWaitlist Priority for Hepatocellular Carcinoma Beyond Milan Criteria: A Potentially Appropriate Decision Without a Structured Approach
American Journal of Transplantation 2014; 14: 79 87 Wiley Periodicals Inc. C Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/ajt.12530
More informationWHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC?
WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC? Dr. Alexander Kim Chief, Vascular and Interventional Radiology, Medstar Georgetown University Hospital, USA DISCLAIMER Please note: The views
More informationGuidelines for SIRT in HCC An Evolution
Guidelines for SIRT in HCC An Evolution 2 nd Asia Pacific Symposium on Liver- Directed Y-90 Microspheres Therapy 1st November 2014, Singapore The challenge of HCC Surgery is potentially curative in early
More informationNew York State HCV Provider Webinar Series. Side Effects of Therapy
New York State HCV Provider Webinar Series Side Effects of Therapy Objectives Understand the basics of HCV therapy Review the currently available regimens for treatment of HCV Appreciate side effects related
More informationUPDATE ON LIVER TRANSPLANTATION IN HIV JAMES O BEIRNE Royal Free Hospital
UPDATE ON LIVER TRANSPLANTATION IN HIV 2013 JAMES O BEIRNE Royal Free Hospital 50 years of Liver Transplantation Surgical & Medical innovation Patient selection Causes of death in HIV Includes primary
More informationTreating now vs. post transplant
Resistance with treatment failure Treating now vs. post transplant Pros (for treating pre transplant) If SVR efficacy means Better quality of life Removal from waiting list No post transplant recurrence
More informationHEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT
HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT INTRODUCTION: Hepatocellular carcinoma (HCC): Fifth most common cancer worldwide Third most common cause of cancer mortality In Egypt: 2.3%
More informationImpact of Sustained Virologic Response with Direct-Acting Antiviral Treatment on Mortality in Patients
Impact of Sustained Virologic Response with Direct-Acting Antiviral Treatment on Mortality in Patients with Advanced Liver Disease Lisa I. Backus MD PhD, Pamela S. Belperio PharmD, Troy A. Shahoumian PhD
More informationHepatitis C in Disclosures
Hepatitis C in 2018 Sandeep Mukherjee, MD CHI Health and Creighton University Medical Center Division of Gastroenterology Grant support: Abbvie Disclosures Speaker: Abbvie, Gilead, Merck Section editor
More informationUpdate on HIV-HCV Epidemiology and Natural History
Update on HIV-HCV Epidemiology and Natural History Jennifer Price, MD Assistant Clinical Professor of Medicine University of California, San Francisco Learning Objectives Upon completion of this presentation,
More informationANTIVIRAL THERAPY FOR HCV. Alfredo Alberti
CLINICAL IMPACT OF SVR AFTER ANTIVIRAL THERAPY FOR HCV Alfredo Alberti Department of Histology,Microbiology and Medical Biotechnologies Molecular Hepatology Unit Venetian Institute of Molecular Medicine
More informationHCC RADIOLOGIC DIAGNOSIS
UCSF Transplant 2010 THE BEFORE AND AFTER HEPATOCELLULAR CARCINOMA MANAGEMENT Francis Yao, M.D. Professor of Clinical Medicine and Surgery Medical Director, Liver Transplantation University of California,
More informationAbstract and Introduction. Patients and Methods. M. Hedenstierna; A. Nangarhari; A. El-Sabini; O. Weiland; S.
www.medscape.com Cirrhosis, High Age and High Body Mass Index Are Risk Factors for Persisting Advanced Fibrosis After Sustained Virological Response in Chronic Hepatitis C M. Hedenstierna; A. Nangarhari;
More informationAUTHOR QUERY FORM. Please check this box if you have no corrections to make to the PDF file. Journal: JHEPAT
Our reference: JHEPAT 6166 P-authorquery-v13 AUTHOR QUERY FORM Journal: JHEPAT Please e-mail your responses and any corrections to: E-mail: proofcorrections.esnl@elsevier.sps.co.in Article Number: 6166
More informationWhite Nights of Hepatology 2016
White Nights of Hepatology 2016 Saint Petersburg, 3 June 2016 Long-term treatment of Chronic hepatitis B - a key to HCC prevention Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow
More informationRecurrent HCV after a Pre-LTx Course of SOF/DAC:
Recurrent HCV after a Pre-LTx Course of SOF/DAC: Didier Samuel, Teresa Antonini Centre Hépato-Biliaire, Inserm Paris Sud Research Unit 1193 Hôpital Paul Brousse, Villejuif, France 3 rd Optimize Workshop,
More information